Bin Wu1, Jin-Shui Zhu, Yi Zhang, Wei-Ming Shen, Qiang Zhang. 1. Department of Gastroenterology, Shanghai Sixth Hospital Affiliated to Shanghai Jiaotong University, Yishang Road 600, Shanghai 200223, China.
Abstract
AIM: To investigate the predictive clinical value of in vitro 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay for directing chemosensitivity in patients with gastric cancer. METHODS: Results of a total of 353 consecutive patients with gastric cancer treated with MTT-directed chemotherapy or physician's empirical chemotherapy from July 1997 to April 2003 were reviewed and analyzed retrospectively. RESULTS: The overall 5-year survival rate of MTT-sensitive group (MSG) and control group (CG) was 47.5% and 45.1%, respectively. The results of subgroup analysis with Cox proportional-hazards model were favorable for the MSG-sensitive group. However, no statistically significant difference in survival rate was observed between the two groups. CONCLUSION: Individualized chemotherapy based on in vitro MTT assay is beneficial, but needs to be confirmed by further randomized controlled trials.
AIM: To investigate the predictive clinical value of in vitro 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay for directing chemosensitivity in patients with gastric cancer. METHODS: Results of a total of 353 consecutive patients with gastric cancer treated with MTT-directed chemotherapy or physician's empirical chemotherapy from July 1997 to April 2003 were reviewed and analyzed retrospectively. RESULTS: The overall 5-year survival rate of MTT-sensitive group (MSG) and control group (CG) was 47.5% and 45.1%, respectively. The results of subgroup analysis with Cox proportional-hazards model were favorable for the MSG-sensitive group. However, no statistically significant difference in survival rate was observed between the two groups. CONCLUSION: Individualized chemotherapy based on in vitro MTT assay is beneficial, but needs to be confirmed by further randomized controlled trials.
Authors: C G Taylor; J M Sargent; A W Elgie; C J Williamson; G M Lewandowicz; O Chappatte; J G Hill Journal: Eur J Gynaecol Oncol Date: 2001 Impact factor: 0.196
Authors: Reid M Wainess; Justin B Dimick; Gilbert R Upchurch; John A Cowan; Michael W Mulholland Journal: J Gastrointest Surg Date: 2003-11 Impact factor: 3.452
Authors: Stuart J Mercer; Shaw S Somers; Louise A Knight; Pauline A Whitehouse; Sanjay Sharma; Federica Di Nicolantonio; Sharon Glaysher; Simon Toh; Ian A Cree Journal: Anticancer Drugs Date: 2003-07 Impact factor: 2.248
Authors: Patrick D Bhola; Eman Ahmed; Jennifer L Guerriero; Ewa Sicinska; Emily Su; Elizaveta Lavrova; Jing Ni; Otari Chipashvili; Timothy Hagan; Marissa S Pioso; Kelley McQueeney; Kimmie Ng; Andrew J Aguirre; James M Cleary; David Cocozziello; Alaba Sotayo; Jeremy Ryan; Jean J Zhao; Anthony Letai Journal: Sci Signal Date: 2020-06-16 Impact factor: 8.192
Authors: Molly M Morgan; Brian P Johnson; Megan K Livingston; Linda A Schuler; Elaine T Alarid; Kyung E Sung; David J Beebe Journal: Pharmacol Ther Date: 2016-05-21 Impact factor: 12.310